Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SHE:000766)
China · Delayed Price · Currency is CNY 14.61
-0.16 (-1.08%)
Nov 6, 2026, 3:04 PM CST
SHE:000766 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,013 | 1,169 | 1,322 | 1,470 | 1,470 | 1,514 |
Other Revenue | 1.26 | 1.26 | 0.5 | 3.57 | 0.58 | 1.32 |
| 1,014 | 1,170 | 1,323 | 1,473 | 1,471 | 1,515 | |
Revenue Growth | -18.61% | -11.54% | -10.23% | 0.18% | -2.95% | 36.31% |
Cost of Revenue | 274.71 | 325.01 | 329.03 | 381.17 | 352.93 | 350.18 |
Gross Profit | 739.58 | 844.95 | 993.53 | 1,092 | 1,118 | 1,165 |
Selling, General & Admin | 586.7 | 677.13 | 789.26 | 905 | 923.47 | 986.24 |
Research & Development | 45.3 | 39.85 | 50.34 | 45.82 | 64.91 | 63.52 |
Other Operating Expenses | 19.94 | 14.08 | 9.88 | 10.62 | 11.57 | 5.4 |
Operating Expenses | 651.05 | 730.43 | 853.14 | 970.43 | 996.86 | 1,052 |
Operating Income | 88.53 | 114.52 | 140.39 | 121.75 | 120.96 | 113.33 |
Interest Expense | -85.24 | -81.89 | -84.98 | -83.15 | -88.79 | -97.19 |
Interest & Investment Income | 6.36 | 7 | 5.28 | 4.02 | 11.5 | 26.36 |
Other Non Operating Income (Expenses) | -3.59 | -4.43 | -2.66 | 1.23 | -3.64 | 3.47 |
EBT Excluding Unusual Items | 6.06 | 35.2 | 58.03 | 43.85 | 40.02 | 45.98 |
Gain (Loss) on Sale of Investments | -0.04 | -0.03 | 0.03 | -2.61 | -0.05 | -0.01 |
Gain (Loss) on Sale of Assets | 0 | -0.05 | -0.17 | -0.21 | -0.02 | 0.83 |
Asset Writedown | -3.96 | -0.28 | -0.12 | 0.22 | -0.11 | -1.49 |
Other Unusual Items | 12.31 | 7.86 | 9.32 | 13.61 | 10.33 | 14.32 |
Pretax Income | 14.38 | 42.71 | 67.09 | 54.86 | 50.17 | 59.62 |
Income Tax Expense | 3.3 | 8.51 | 11.11 | 11.63 | 20.99 | 25.64 |
Earnings From Continuing Operations | 11.08 | 34.2 | 55.98 | 43.23 | 29.19 | 33.99 |
Minority Interest in Earnings | 0.22 | 0.08 | 0.46 | 0.71 | 0.96 | 1.29 |
Net Income | 11.3 | 34.29 | 56.44 | 43.93 | 30.15 | 35.27 |
Net Income to Common | 11.3 | 34.29 | 56.44 | 43.93 | 30.15 | 35.27 |
Net Income Growth | -80.35% | -39.25% | 28.46% | 45.71% | -14.52% | - |
Shares Outstanding (Basic) | 871 | 857 | 941 | 879 | 1,005 | 882 |
Shares Outstanding (Diluted) | 871 | 857 | 941 | 879 | 1,005 | 882 |
Shares Change | -7.61% | -8.87% | 7.05% | -12.57% | 13.97% | -9.24% |
EPS (Basic) | 0.01 | 0.04 | 0.06 | 0.05 | 0.03 | 0.04 |
EPS (Diluted) | 0.01 | 0.04 | 0.06 | 0.05 | 0.03 | 0.04 |
EPS Growth | -78.73% | -33.33% | 20.00% | 66.67% | -25.00% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 52.04 | 40.99 | 113.58 | 86.11 | 174.42 | 112.85 |
Free Cash Flow Per Share | 0.06 | 0.05 | 0.12 | 0.10 | 0.17 | 0.13 |
Gross Margin | 72.92% | 72.22% | 75.12% | 74.13% | 76.00% | 76.89% |
Operating Margin | 8.73% | 9.79% | 10.62% | 8.26% | 8.22% | 7.48% |
Profit Margin | 1.11% | 2.93% | 4.27% | 2.98% | 2.05% | 2.33% |
Free Cash Flow Margin | 5.13% | 3.50% | 8.59% | 5.85% | 11.86% | 7.45% |
EBITDA | 147.03 | 175.63 | 204.98 | 196.49 | 192.58 | 182.72 |
EBITDA Margin | 14.50% | 15.01% | 15.50% | 13.34% | 13.09% | 12.06% |
D&A For EBITDA | 58.5 | 61.11 | 64.59 | 74.74 | 71.62 | 69.39 |
EBIT | 88.53 | 114.52 | 140.39 | 121.75 | 120.96 | 113.33 |
EBIT Margin | 8.73% | 9.79% | 10.62% | 8.26% | 8.22% | 7.48% |
Effective Tax Rate | 22.95% | 19.92% | 16.56% | 21.20% | 41.83% | 42.99% |
Revenue as Reported | 1,014 | 1,170 | 1,323 | 1,473 | 1,471 | 1,515 |
Advertising Expenses | - | 274.54 | 249.73 | 352.83 | 298.68 | 375.06 |